780. Activity of Eravacycline Against North American and European Enterobacteriaceae, Including Multidrug-Resistant Isolates, Collected in 2013-14
Session: Poster Abstract Session: Antimicrobial Agents: Novel Agents
Friday, October 9, 2015
Room: Poster Hall
Posters
  • IDWeek2015_Eravacycline in vitro activity_Enterobacteriacae_FINAL.pdf (140.4 kB)
  • Background: Eravacycline is a novel, fully synthetic fluorocycline antibiotic with broad-spectrum activity available in intravenous and oral formulations for the treatment of multidrug-resistant (MDR) infections. Eravacycline has recently completed two Phase 3 studies for the treatment of complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI).

    Methods: Clinical isolates of Enterobacteriaceae (ENT) from Europe and North America collected in 2013-2014 (n=4,462) comprising 15 species and MDR isolates were tested.  MICs were determined by broth microdilution according to CLSI guidelines for eravacycline and comparators. MDR was defined as resistant to 3 or more from cefepime/ceftazidime/ceftriaxone (any one), gentamicin, imipenem, levofloxacin, piperacillin-tazobactam or tetracycline.  Quality control testing was performed on each day of testing as specified by the CLSI.

    Results : Eravacycline results for all ENT and major species collected are shown in the following Table:

    Organism/MIC (ĩg/ml)

    Europe

    North America

    N

    MIC50

    MIC90

    MIN

    MAX

    N

    MIC50

    MIC90

    MIN

    MAX

    All ENT

    1739

    0.5

    2

    0.06

    16

    2723

    0.5

    2

    0.06

    8

    All ENT (MDR)

    269

    0.5

    2

    0.06

    16

    285

    1

    4

    0.06

    8

    C. freundii

    149

    0.25

    0.5

    0.12

    1

    137

    0.25

    0.5

    0.06

    4

    C. koseri

    149

    0.25

    0.25

    0.12

    1

    69

    0.25

    0.25

    0.12

    0.5

    E. aerogenes

    150

    0.5

    0.5

    0.12

    2

    349

    0.5

    1

    0.12

    8

    E. cloacae

    148

    0.5

    1

    0.12

    8

    347

    0.5

    1

    0.12

    8

    E. cloacae (MDR)

    29

    1

    4

    0.25

    8

    45

    0.5

    4

    0.25

    8

    E. coli

    153

    0.12

    0.25

    0.06

    2

    349

    0.12

    0.25

    0.06

    2

    E. coli (MDR)

    42

    0.12

    0.25

    0.06

    0.5

    56

    0.25

    0.5

    0.06

    2

    K. oxytoca

    150

    0.25

    0.25

    0.12

    2

    347

    0.25

    0.5

    0.06

    8

    K. pneumoniae

    147

    0.5

    1

    0.12

    2

    350

    0.5

    1

    0.12

    8

    K. pneumoniae (MDR)

    55

    0.5

    1

    0.12

    2

    47

    1

    2

    0.25

    4

    M. morganii

    149

    1

    2

    0.25

    8

    67

    2

    4

    0.25

    8

    P. mirabilis

    150

    2

    2

    0.25

    4

    258

    1

    2

    0.25

    8

    P. mirabilis (MDR)

    31

    2

    2

    0.5

    4

    43

    2

    4

    0.25

    4

    P. stuartii

    57

    1

    4

    0.5

    16

    27

    1

    4

    0.5

    8

    S. marcescens

    150

    1

    2

    0.5

    8

    347

    1

    2

    0.5

    8

    MIN, minimum MIC; MAX, maximum MIC

    Conclusion: Eravacycline was very active against Enterobacteriaceae collected from Europe and North America.  The MDR phenotype had little or no effect on eravacycline MIC.  The MIC90 ranged from 0.25 - 4 ĩg/ml in both geographical regions. Overall, eravacycline showed promising activity and data from the Phase 3 trials will be used in determining the clinical breakpoints.

    Ian Morrissey, PhD1, Joyce Sutcliffe, PhD2, Meredith Hackel, PhD, MPH3 and Stephen Hawser, PhD1, (1)IHMA Europe Sārl, Epalinges, Switzerland, (2)Biology, Tetraphase Pharmaceuticals, Inc., Watertown, MA, (3)International Health Management Associates, Inc., Schaumburg, IL

    Disclosures:

    I. Morrissey, IHMA Europe Sārl: Independent Contractor , Consulting fee

    J. Sutcliffe, Tetraphase Pharmaceuticals: Employee , Salary

    M. Hackel, IHMA, Inc.: Independent Contractor , Consulting fee

    S. Hawser, IHMA Europe Sārl: Independent Contractor , Consulting fee

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.